Zhejiang Taimei Medical Technology Co., Ltd. (“Taimei Tech”) disclosed that it repurchased 219,600 H-shares on the Hong Kong Stock Exchange on 20 October 2026. The shares were acquired on-market at prices ranging from HKD 4.265 to HKD 4.52, for a total consideration of HKD 0.97 million, implying a volume-weighted average cost of roughly HKD 4.41 per share.
Following the transaction, Taimei Tech’s outstanding H-share count (excluding treasury shares) fell to 189.86 million from 190.08 million, representing a 0.12% reduction. Treasury share holdings rose to 10.73 million, while the company’s total issued share capital remained unchanged at 200.59 million shares.
The purchase was executed under the share-repurchase mandate approved on 23 June 2026, which authorises the company to buy back up to 20.02 million shares. Cumulative repurchases under this mandate now stand at 10.31 million shares, equivalent to 5.15% of the company’s issued share capital at the date the mandate was granted. The mandated 30-day moratorium on new share issues or treasury-share disposals runs through 19 November 2026.
Executive Director and Joint Company Secretary Ni Xiaomei confirmed that the repurchases complied with Hong Kong listing rules and the company’s previously published Explanatory Statement.
Comments